ArticleThe Journal of infectious diseases2025
Rotavirus Vaccine Effectiveness Stratified By National-Level Characteristics: An Introduction to the 24-Country MNSSTER-V Project, 2007-2023.
Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Immune response to rotavirus vaccines in low- and middle-income countries: Challenges and perspectives.Human vaccines & immunotherapeutics · 2026Review
- Article
- Evaluation of Rotavirus Vaccine Effectiveness by Severity of Rotavirus Disease: Findings From the MNSSTER-V Project.The Pediatric infectious disease journal · 2026Article
- Rotavirus mucosal immunology: insights and research priorities from an international convening in Liverpool, March 2024.NPJ vaccines · 2026Article
- Real-World Effectiveness of Rotavirus Vaccine Against Rotavirus Disease Among Children < 2 Year of Age in Mali.Journal of the Pediatric Infectious Diseases Society · 2026Article
- Oral rotavirus vaccine effectiveness among malnourished children in 19 countries: Findings from the MNSSTER-V project.Journal of pediatric gastroenterology and nutrition · 2026Article
- A report for the fifth International Workshop on Rotavirus and Norovirus in China.Human vaccines & immunotherapeutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
Abstract
backgroundRotavirus vaccines are moderately protective against illness in settings with high compared with low mortality rates. Vaccine effectiveness (VE) evaluations may clarify our understanding of these disparities, but estimates among key subpopulations and against rare outcomes are not available in many analyses due to sample size. We combined 25 data sets from test-negative design case-control evaluations in 24 countries that enrolled children with medically attended diarrhea, laboratory-confirmed rotavirus stool testing, and documented vaccination status. We calculated rotavirus VE stratified by country-level characteristics.
methodsChildren 3-59 months old with birthdates and surveillance hospital arrival dates were included; other variables were standardized as available. Children were considered vaccinated if they received ≥1 dose of rotavirus vaccine >14 days before arrival. We summarized child- and country-level characteristics, including national <5-year-old mortality rate (U5M). Following the manufacturer recommended dose schedule, complete- and partial-series adjusted VE were estimated using logistic regression models.
resultsWe included 6626 rotavirus-positive children (case patients) and 19 459 rotavirus negative children (controls). Adjusted complete-series VE was significantly higher among children from countries in the low and medium U5M stratum (74% [95% confidence interval, 64%-81%]) compared with all groups within the high U5M stratum (range, 52% [42%-60%]) to 46% [31%-57%]). Partial-series estimates were lower than complete-series estimates.
conclusionsThese findings are consistent with the published literature, though they suggest heterogeneity in vaccine performance within broad child mortality rate levels. Our findings also highlight the importance of complete-series vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.